Evaluating Bias Reduction Methods in Binary Emax Model for Reliable Dose-Response Estimation
Jiangshan Zhang 1 , Vivek Pradhan 2 , Yuxi Zhao 2 1 Department of Statistics, University of California, Davis 2 I&I and Specialty Care Statistics, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139, USA · 2025
Read Evaluating Bias Reduction Methods in Binary Emax Model for Reliable Dose-Response Estimation by Jiangshan Zhang 1 , Vivek Pradhan 2 , Yuxi Zhao 2 1 Department of Statistics, University of California, Davis 2 I&I and Specialty Care Statistics, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139, USA (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2509-18459.txt.
Introduction
Drug dose trials need a sound read on how response rises with dose. Jiangshan Zhang, Vivek Pradhan, and Yuxi Zhao study the Binary Emax model, a standard curve for such trials, in this 2025 paper. Trials in phase II are often small, and the usual estimation method leans on large-sample theory. That can bias the dose picked for later trials.
The team compares three bias-reduction methods: a classic correction, the Firth score tweak, and a penalized likelihood method using the Jeffreys prior. Wide simulations test bias and spread, including cases where the model form is wrong. The Firth and penalized methods both proved robust. The penalized method was most stable, with lower variance. A case study on a real phase II trial shows the methods at work. The authors recommend the penalized route when response may not rise smoothly.
Catalog record
| CREATOR | Jiangshan Zhang 1 , Vivek Pradhan 2 , Yuxi Zhao 2 1 Department of Statistics, University of California, Davis 2 I&I and Specialty Care Statistics, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139, USA |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2509-18459
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Evaluating Bias Reduction Methods in Binary Emax Model for Reliable Dose-Response Estimation Jiangshan Zhang 1 , Vivek Pradhan 2 , Yuxi Zhao 2 1 Department of Statistics, University of California, Davis 2 I&I and Specialty Care Statistics, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139, USA Abstract The Binary Emax model is widely employed in dose-response analysis during Phase II clinical studies to identify the optimal dose for subsequence confirmatory trials. The parameter estimation and inference heavily rely on the asymptotic properties of Maximum Likelihood (ML) estimators; however, this approach may be questionable under small or moderate sample sizes and is not robust to violation of model assumption. To provide a reliable solution, this paper examines three bias-reduction methods: the Cox-Snell bias correction, Firth’s score modification, and a maximum penalized likelihood estimator (MPLE) using Jeffreys prior. Through comprehensive simulation studies, we evaluate the performance of these methods in reducing bias and controlling variance, especially when model assumptions are violated. The results demonstrate that both Firth’s and MPLE methods provide robust estimates, with MPLE outperforming in terms of stability and lower variance. We further illustrate the practical application of these methods using data from the TURANDOT ( Vermeire et al. 2017b ) study, a Phase II clinical trial. Our findings suggest that MPLE with Jeffreys prior offers an effective and reliable alternative to Firth’s method, particularly for dose-response relationships that deviate from monotonicity, making it valuable for robust parameter estimation in dose-ranging studies. Keywords— Binary Emax model, Small sample size, Firth correction, Bias-reduction, Penalized maximum likelihood 1 Introduction In drug development, accurately estimating the dose-response relationship for an experimental compound is a critical step. This process involves assessing how varying doses of the compound influence its therapeutic effects, enabling researchers to identify the optimal dosage that maximizes efficacy while minimizing risks or adverse effects. Phase II clinical trials, particularly early-stage multigroup parallel trials, are designed to evaluate the efficacy of a compound across a range of dose levels. In analyses, the Emax model is a popular choice to characterize non-linear dose-response relationships. It can be implemented for various efficacy endpoints approved by the regulatory agency, such as binary (e.g., responder vs. non-responder), continuous (e.g., biomarker change from baseline), and time-to-event (e.g., progression-free survival, overall survival). In this paper we focus on a dichotomized endpoint, which makes the binary Emax model an appropriate choice for analysis. Extensions to other endpoint types follow analogous likelihood-based formulations and are left to future work. Let n denote the total sample size, and suppose y_{i} denotes the binary outcome for the i -th patient randomized to a dose Dose_{i} , where Dose_{i} is one of the predefined dose levels from a set of M levels \{D_{1},\cdots,D_{M}\} , for i=1,\cdots,n . Without loss of generality, let P(y_{i}=1|Dose_{i})=\pi_{i} be the probability of success for patient i after dosage. Without other covariates, \pi_{i} would be one of M possible probability levels, corresponding to administered dose levels. Under this setup, the sigmoid four-parameter Emax model can be written as the following log\left(\frac{\pi_{i}}{1-\pi_{i}}\right)=E_{0}+\frac{E_{max}\times Dose_{i}^{\lambda}}{ED_{50}^{\lambda}+Dose_{i}^{\lambda}} (1) where E_{0} is the expected logit of dose effect at Dose_{i}=0 , with Dose_{i}=0 often being considered as placebo; E_{max} is the expected logit of the maximum achievable effect (at infinite dose, can be positive or negative); ED_{50} is the dose that produces half-maximal effect E_{max}/2 (typcially ED_{50}>0 ); and \lambda is the positive slope factor or Hill parameter, determining the steepness of the dose-response curve: larger \lambda yields a sharper, more sigmoidal transition around ED_{50} . Despite its added flexibility, the four-parameter Emax model is often unnecessary; meta-analyses report that the three-parameter Emax model with \lambda=1 fits most empirical dose–response datasets comparably well ( Thomas & Roy 2017a ; Kirby et al. 2011a ; Wu et al. 2017a ) . Hence the Emax model is reduced to \log\left(\frac{\pi_{i}}{1-\pi_{i}}\right)=E_{0}+\frac{E_{max}\times Dose_{i}}{ED_{50}+Dose_{i}}. (2) While the maximum likelihood estimates (MLE) of the three parameters are asymptotically consistent under regulatory conditions, it is well known that the estimates tend to be biased with finite sample size. For the binary Emax model, the estimation process is more complicated and requires careful attention to several key issues: 1. Separation in binary models. When fitting binary outcome models, a common issue that may arise in a small sample setup is the non-convergence of estimates. This phenomenon is often referred as “separation” ( Albert & Anderson 1984a ). Complete separation occurs when a single covariate or a linear combination of covariates perfectly predicts the outcome, leading to divergence in the estimation process. Even in the absence of complete separation, quasi-complete separation—where a subset of subjects’ responses is perfectly predicted—can still pose significant challenges for estimation ( Altman et al. 2004a ). Practical warning signs of separation are: non-convergnece of the estimation algorithm, very large estimated coefficient and standard error pairs, and fitted probabilities numerically equal to 0 or 1 for some pattern of predictors. Separation can be diagnosed formally via linear-programming tests ( Albert & Anderson 1984a ) or with modern implementations that detect separation before fitting (e.g., detect_separation function in R package brglm2 ; see Kosmidis & Firth 2020a ). Although separation is common in biomedical research data, it is often overlooked, particularly when sample sizes are limited. For instance, existing methods and packages that utilize maximum likelihood estimation for dose-response or Emax models, such as the ClinDR package in R developed by Thomas et al. 2017a and the Dosefinding package by Bornkamp et al. 2010a , do not address the issue of separation. 2.Non-monotonic/Convex increasing sample response curve. It is known that the Emax model is a simple concave function that increases monotonically with dose. However, sampling variability from finite small sizes can also cause maximum likelihood estimation non-convergence. This issue is well-documented for continuous outcomes, and several studies have examined the convergence problems of estimation algorithms ( Flournoy et al. 2020a ; Flournoy et al. 2021a ; Chen et al. 2023a ). It has been studied theoretically that the maximum likelihood method tends to fail in two scenarios: when the sample data follow a non-increasing concave shape, or when the data follow a convex increasing shape ( Aletti et al. 2025a ). In a practical view, when this issue arises, one can always provide a sensitivity fit with a more flexible candidate, such as a quadratic-logit model or beta model. A detail demonstration is given in the supplementary material. To address these two issues in the framework of the Emax model, modified likelihood estimation methods were often considered. Heinze & Schemper 2002a and Heinze 2006a demonstrated that Firth’s modified score equations method ( Firth 1993a ), originally developed to reduce bias in maximum likelihood estimates (MLE), can also effectively handle the issue of separation within the framework of generalized linear models (GLMs). Although it has been investigated for the first ill-defined scenario of the Emax model mentioned above, Firth’s method cannot provide admissible estimations for Emax parameters. Even though it can produce a finite estimate under the second scenario mentioned above ( Aletti et al. 2025a ), this score adjustment is not equivalent to maximizing a penalized likelihood in nonlinear models such as Emax. This complicates implementation for methods that require explicit likelihood functions. It draws our attention that modifying the